Literature DB >> 9266503

Coenzyme Q deficiency in mitochondria: kinetic saturation versus physical saturation.

G Lenaz1, G Parenti Castelli, M D'Aurelio, C Bovina, G Formiggini, M Marchetti, E Estornell, H Rauchova.   

Abstract

The coenzyme Q (CoQ) concentration in the inner membrane of beef heart mitochondria is not kinetically saturating for NADH oxidation inasmuch as the K(m) of NADH oxidation for endogenous CoQ10 is in the mM range in membrane lipids. Using CoQ1 as an electron acceptor from complex I, we have found additional evidence that the high Km of NADH oxidase for CoQ is not an artifact due to the use of organic solvents in reconstitution studies. We have also obtained experimental evidence that CoQ concentration may be rendered more rate-limiting for NADH oxidation either by a decrease of CoQ content (as in liver regeneration or under an acute oxidative stress), or by a possible increase of the Km for CoQ, as in some mitochondrial diseases and ageing. The possibility of enhancing the rate of NADH oxidation by CoQ therapy is hindered by the fact that the CoQ concentration in mitochondria appears to be regulated by its mixability with the membrane phospholipids. Nevertheless CoQ10 incorporated into heart submitochondrial particles by sonication enhances NADH oxidation (but not succinate oxidation) up to twofold. Nontoxic CoQ homologs and analogs having shorter side-chains with respect to CoQ10 can be incorporated in the mitochondrial membrane without sonication, supporting an enhancement of NADH oxidation rate above 'physiological' values. It is worth investigating whether this approach can have a therapeutical value in vivo in mitochondrial bioenergetic disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266503     DOI: 10.1016/s0098-2997(97)00029-0

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  6 in total

Review 1.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; C Colomé; M A Vilaseca; C Sierra; F J Cambra; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

3.  Decylubiquinone increases mitochondrial function in synaptosomes.

Authors:  Jayne E Telford; Seán M Kilbride; Gavin P Davey
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

4.  Investigation of the mechanism of proton translocation by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria: does the enzyme operate by a Q-cycle mechanism?

Authors:  Steven Sherwood; Judy Hirst
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

5.  Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2.

Authors:  Jinlian Li; Shuting Zheng; Ting Cheng; Yuanyuan Li; Xiaobin Mai; Guangchun Jiang; Yongxia Yang; Qianqian Zhang; Jiangchao Li; Lingyun Zheng; Lijing Wang; Cuiling Qi
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

6.  The submitochondrial distribution of ubiquinone affects respiration in long-lived Mclk1+/- mice.

Authors:  Jérôme Lapointe; Ying Wang; Eve Bigras; Siegfried Hekimi
Journal:  J Cell Biol       Date:  2012-10-08       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.